Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response

References

• Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I, Bray F. Cancer Today. Lyon, France: International Agency for Research on Cancer; 2016 Available from: http://gco.iarc.fr/today Accessed 609, 2018.
   Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–S192. doi:10.1016/S0020-7292(06)60033-7
   PubMed Web of Science ®Google Scholar
• Koch M, Krieger ML, Stolting D, et al. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling. Biochem Pharmacol. 2013;85(8):1077–1090. doi:10.1016/j.bcp.2013.01.02823396090
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer. 2011;73(3):256–263. doi:10.1016/j.lungcan.2011.04.01421620512
   PubMed Web of Science ®Google Scholar
• Walter RF, Vollbrecht C, Werner R, et al. Screening of pleural mesotheliomas for DNA-damage repair players by digital gene expression analysis can enhance clinical management of patients receiving platin-based chemotherapy. J Cancer. 2016;7(13):1915–1925. doi:10.7150/jca.1639027698933
   PubMed Web of Science ®Google Scholar
• Ting S, Mairinger FD, Hager T, et al. ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 2013;14(5):558–567. e553. doi:10.1016/j.cllc.2013.04.01323810210
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Werner R, Flom E, et al. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 2017. doi:10.1007/s00428-017-2133-z
   PubMed Web of Science ®Google Scholar
• Bolis G, Scarfone G, Luchini L, et al. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. Eur J Cancer. 1994;30A(12):1764–1768. doi:10.1016/0959-8049(94)e0125-n7880602
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.38421892204
   PubMed Web of Science ®Google Scholar
• Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706–721. doi:10.1124/pr.111.00563722659329
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa02017712529460
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–18543. doi:10.1073/pnas.050918210216344461
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365. doi:10.1073/pnas.061153310417360651
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm109315322536
   PubMed Web of Science ®Google Scholar
• Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4(7):e6412. doi:10.1371/journal.pone.000641219641607
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141(2):293–302. doi:10.1016/j.ygyno.2016.03.00826972336
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa120069422658128
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022. doi:10.1200/JCO.2015.62.339726351349
   PubMed Web of Science ®Google Scholar
• Mariya T, Hirohashi Y, Torigoe T, et al. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer. Cancer Immunol Res. 2014;2(12):1220–1229. doi:10.1158/2326-6066.CIR-14-010125324403
   PubMed Web of Science ®Google Scholar
• Lo CS, Sanii S, Kroeger DR, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925–934. doi:10.1158/1078-0432.CCR-16-143327601594
   PubMed Web of Science ®Google Scholar
• Tan JX, Dao FY, Lv H, Feng PM, Ding H. Identifying phage virion proteins by using two-step feature selection methods. Molecules. 2018;23(8). doi:10.3390/molecules23082000
   Web of Science ®Google Scholar
• Yin XH, Wang ZQ, Yang SZ, Jia HY, Shi M. Clinical observation of laparoscopic radical hysterectomy for cervical cancer. Int J Clin Exp Med. 2014;7(5):1373–1377.24995098
   PubMed Web of Science ®Google Scholar
• Long WL, Liang P, Liu S, Zuo, Y. Transcriptome comparisons of multi-species identify differential genome activation of mammals embryogenesis. IEEE Access. 2019;7:7794–7802. doi:10.1109/ACCESS.2018.2889809
   Web of Science ®Google Scholar
• Yang L, Wang J, Wang H, Lv Y, Zuo Y, Jiang W. Analysis and identification of toxin targets by topological properties in protein-protein interaction network. J Theor Biol. 2014;349:82–91. doi:10.1016/j.jtbi.2014.02.00124512914
   PubMed Web of Science ®Google Scholar
• Yang L, Wang J, Wang H, et al. Analysis and identification of essential genes in humans using topological properties and biological information. Gene. 2014;551(2):138–151. doi:10.1016/j.gene.2014.08.04625168893
   PubMed Web of Science ®Google Scholar
• Waggott D, Chu K, Yin S, Wouters BG, Liu FF, Boutros PC. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012;28(11):1546–1548. doi:10.1093/bioinformatics/bts18822513995
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Walter RF, Werner R, et al. Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carcinomas and is crucial for carcinoid tumourgenesis. J Cancer. 2014;5(6):465–471. doi:10.7150/jca.923524959299
   PubMed Web of Science ®Google Scholar
• Walter RF, Werner R, Ting S, et al. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. Oncotarget. 2015. doi:10.18632/oncotarget.3992
   Google Scholar
• Walter RF, Mairinger FD, Werner R, et al. SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString). Future Oncol. 2015;11(7):1027–1036. doi:10.2217/fon.15.1825804118
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Werner R, Flom E, et al. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 2017;470(6):627–637. doi:10.1007/s00428-017-2133-z28466156
   PubMed Web of Science ®Google Scholar
• Ollikainen T, Linnainmaa K, Kinnula VL. DNA single strand breaks induced by asbestos fibers in human pleural mesothelial cells in vitro. Environ Mol Mutagen. 1999;33(2):153–160.10217069
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204. doi:10.1038/nrc234218256616
   PubMed Web of Science ®Google Scholar
• Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1987;19(2):149–154. doi:10.1007/bf002545683568272
   PubMed Web of Science ®Google Scholar
• Surowiak P, Kaplenko I, Spaczynski M, Zabel M. The expression of metallothionein (MT) and proliferation intensity in ovarian cancers treated with cisplatin and paclitaxel. Folia Morphol (Warsz). 2003;62(4):493–495.14655150
   PubMedGoogle Scholar
• Choi CH, Cha YJ, An CS, et al. Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein. Cancer Cell Int. 2004;4(1):6. doi:10.1186/1475-2867-4-615494073
   PubMedGoogle Scholar
• Surowiak P, Materna V, Maciejczyk A, et al. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch. 2007;450(3):279–285. doi:10.1007/s00428-006-0362-717235562
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Schmeller J, Borchert S, et al. Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Oncotarget. 2018;9(32):22254–22268. doi:10.18632/oncotarget.2496229854276
   PubMedGoogle Scholar
• Wang J, Gao Y, Wang L, et al. A variant (rs932335) in the HSD11B1 gene is associated with colorectal cancer in a Chinese population. Eur J Cancer Prev. 2013;22(6):523–528. doi:10.1097/CEJ.0b013e328365634624061267
   PubMed Web of Science ®Google Scholar
• Walter RF, Mairinger FD, Werner R, et al. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget. 2016;7(15):20166–20179. doi:10.18632/oncotarget.773727064343
   PubMedGoogle Scholar
• Walter RF, Vollbrecht C, Christoph D, et al. Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors. J Cancer. 2016;7(15):2165–2172. doi:10.7150/jca.1692527994651
   PubMed Web of Science ®Google Scholar
• Walter RF, Vollbrecht C, Werner R, et al. microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. Oncotarget. 2016;7(14):18713–18721. doi:10.18632/oncotarget.766626918730
   PubMedGoogle Scholar
• Walter RF, Werner R, Ting S, et al. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. Oncotarget. 2015;6(28):24690–24698. doi:10.18632/oncotarget.399226008974
   PubMedGoogle Scholar
• Walter RF, Werner R, Vollbrecht C, et al. ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP were identified as reference genes in neuroendocrine lung cancer via the nCounter technology. PLoS One. 2016;11(11):e0165181. doi:10.1371/journal.pone.016518127802291
   PubMed Web of Science ®Google Scholar
• Yang L, Wang S, Zhang Q, et al. Clinical significance of the immune microenvironment in ovarian cancer patients. Mol Omics. 2018;14(5):341–351. doi:10.1039/c8mo00128f30129640
   PubMed Web of Science ®Google Scholar